Represent

Donate

Lobbying Relationship

Client

Endo Pharmaceuticals, Inc.

More records

Lobbying firm

Venable LLP

More records

  • Issues relating to incentives for life sciences research; tax treatment of inverted companies; tax issues in mergers and acquisitions of US firms.
  • Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; Issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; Issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market;- Opioid abuse legislation; issues relating to prescription drug pricing.
  • Oversight of implementation of the America Invents Act; issues relating to patent settlements; patent reform; issues relating to misuse of the inter pares review process.

Duration: to

General Issues: Taxation/Internal Revenue Code, Health Issues, Copyright/Patent/Trademark, Pharmacy

Spending: about $1,540,000 (But it's complicated. Here's why.)

Agencies lobbied since 2008: U.S. Senate, House of Representatives

Bills mentioned

H.R.160: Protect Medical Innovation Act of 2015

Sponsor: Erik Paulsen (R-Minn.)

H.R.471: Ensuring Patient Access and Effective Drug Enforcement Act of 2015

Sponsor: Tom Marino (R-Pa.)

S.483: Ensuring Patient Access and Effective Drug Enforcement Act of 2016

Sponsor: Orrin G. Hatch (R-Utah)

S.524: Comprehensive Addiction and Recovery Act of 2016

Sponsor: Sheldon Whitehouse (D-R.I.)

H.R.4641: To provide for the establishment of an inter-agency task force to...

Sponsor: Susan Brooks (R-Ind.)

S.2948: SASCA

Sponsor: Patty Murray (D-Wash.)

H.R.5748: To establish the Adams Memorial Commission to carry out the provisions...

Sponsor: Stephen F. Lynch (D-Mass.)

H.R.5046: Comprehensive Opioid Abuse Reduction Act of 2016

Sponsor: F. James Sensenbrenner (R-Wis.)

H.R.9: Innovation Act

Sponsor: Robert W. Goodlatte (R-Va.)

S.1137: PATENT Act

Sponsor: Charles E. Grassley (R-Iowa)

H.R.106: Restoration of Parental Rights and State Sovereignty Act of 2015

Sponsor: John Culberson (R-Texas)

H.RES.106: Supporting quality of life for prostate cancer patients.

Sponsor: Erik Paulsen (R-Minn.)

H.R.523: Protect Medical Innovation Act of 2013

Sponsor: Erik Paulsen (R-Minn.)

S.232: Medical Device Access and Innovation Protection Act

Sponsor: Orrin G. Hatch (R-Utah)

H.R.486: Stop Tampering of Prescription Pills Act of 2013

Sponsor: Bill Keating (D-Mass.)

H.R.1919: Safeguarding America's Pharmaceuticals Act of 2013

Sponsor: Robert E. Latta (R-Ohio)

H.R.5651: Food and Drug Administration Reform Act of 2012

Sponsor: Fred Upton (R-Mich.)

S.1410: Life Sciences Jobs and Investment Act of 2011

Sponsor: Bob Casey (D-Pa.)

H.R.2632: Life Sciences Jobs and Investment Act of 2011

Sponsor: Devin Nunes (R-Calif.)

H.R.3590: Indonesian Family Refugee Protection Act

Sponsor: Carolyn B. Maloney (D-N.Y.)

H.R.6165: Responsible Child Tax Credit Eligibility Verification Act of 2012

Sponsor: Paul Gosar (R-Ariz.)

H.R.1586: Security Enhancement and Jobs Act of 2011

Sponsor: Peter T. King (R-N.Y.)

H.R.3590: Patient Protection and Affordable Care Act

Sponsor: Charles B. Rangel (D-N.Y.)

S.4018: Life Sciences Jobs and Investment Act of 2010

Sponsor: Bob Casey (D-Pa.)

H.R.6165: Life Sciences Jobs and Investment Act of 2010

Sponsor: Allyson Y. Schwartz (D-Pa.)

H.R.1586: FAA Air Transportation Modernization and Safety Improvement Act

Sponsor: Charles B. Rangel (D-N.Y.)

S.525: Pharmaceutical Market Access and Drug Safety Act of 2009

Sponsor: Byron L. Dorgan (D-N.D.)

H.R.1298: Pharmaceutical Market Access and Drug Safety Act of 2009

Sponsor: Marion Berry (D-Ark.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist Covered positions?
Robert Smith II Legis. Director, U.S. Rep. Wes Watkins Legislative Director, U.S. Rep. Wes Watkins
Samuel Olchyk Legis. Counsel, Jt. Comm. of Taxation Legis. Cnsl, Jt. Comm. on Taxation
Will Norwind Counsel, House Telecom Subcommittee
Bart Stupak U.S. Representative - 1993-2011
Ray Beeman Legis. Cnsl, Jt. Comm. on Taxation
John O'Neill Tax & Pens. Cnsl Sen Fin Com.; Poly Dir Sen Whip
Robert Smith n/a
Robert L. Smith II n/a
William R. Nordwind n/a
William Nordwind n/a
William Norwind n/a
Robert L. Smith n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

Termination
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page